Clinical Trials Browser

Phase 1 × Breast Neoplasms × Epirubicin × Clear all

NCT02897700 2024-04-17

COC-IDCB

Phase 1 Recruiting

Breast Neoplasms

NCT06121570 2023-11-08

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Phase 1 Recruiting

Breast Neoplasms

NCT00002866 2020-04-01

Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms, Neutropenia

NCT01624441 2018-03-30

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

Phase 1 Completed

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00722293 2017-11-13

A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors

Phase 1 Completed

BreastGynecologicSarcoma

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Sarcoma

NCT00322374 2016-03-10

Phase I Combination w/ Epirubicin

Phase 1 Completed

42 enrolled 24 charts

Breast Neoplasms

NCT00753207 2016-02-15

Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30

Phase 1 Completed

Breast Neoplasms

NCT02392845 2015-03-19

MODEL1

Phase 1 Completed

Breast Neoplasms

NCT00008034 2012-07-18

Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer

Phase 1 Completed

Breast Neoplasms, Inflammatory Breast Neoplasms